Grant Recipients
MARROW DONOR DRIVES
1990 - OngoingIn collaboration with The New York Blood Center, New York, NY
PAIN AND PALLIATIVE CARE SERVICE
1997 - OngoingEYTON STEIN, MD
Memorial Sloan Kettering Cancer Center, New York, NY“A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated with Upregulation of HOX Genes”
XIAODI WU, MD, PH.D
Memorial Sloan Kettering Cancer Center, New York, NY“Elucidating the Molecular Pathogenesis of Acute Myeloid Leukemia with CEBPA Mutation”
EYTON STEIN, MD
Memorial Sloan Kettering Cancer Center, New York, NY“A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated with Upregulation of HOX Genes”
XIAODI WU, MD, PH.D
Memorial Sloan Kettering Cancer Center, New York, NY“Elucidating the Molecular Pathogenesis of Acute Myeloid Leukemia with CEBPA Mutation”
MARTINA CARDILLO, PH.D
North Shore – LIJ Feinstein Institute for Medical Research Manhasset, NY“CLL’s and ABC’s: Studies of Shared Phenotypic and Functional Features”
LINGBO ZHANG, PH.D
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY“Targeting Metabolic Vulnerabilities as Novel Therapeutics for Acute Myeloid Leukemia”
OLGA DASHEVSKY, PH.D
Dana-Farber Cancer Center, Boston, MA“CRISPR Studies to Define Response vs. Resistance Mechanisms to Natural Killer Cells for Myeloma/Plasma Cell Leukemia Cells with Defects Conferring T Cell Resistance”
SALIME BENBARCHE, PH.D
Memorial Sloan Kettering Cancer Center, New York, NY“A Novel Gene Therapy Approach to Eliminate Spliceosome Mutant Leukemia”
SHAYNE YIN, PH.D
Dana-Farber Cancer InstituteDissecting the functional effects of mutated IKZF3 in driving Chronic Lymphocytic Leukemia
ANGELA SAVINO, PH.D
MSK Cancer CenterTargeting the dysregulated metabolic program in Acute Myeloid Leukemia
ZAHOLIN YANG, PH.D
Cold Spring Harbor LabNovel synthetic lethality between the Fanconi anemia pathway and ALDH2 in AML
RUKHSANA ASLAM, MD
Feinstein Institute For Medical ResearchRole of the IL-17/TH17 in axis in generating a cytolytic immune response against chronic lymphocytic leukemia in B cells.
RYOSUKE SHIRASAKI, MD
Dana- Farber Cancer Institute Boston, MA“CRISPR studies on mechanisms of resistance to pharmacological degraders of proteins driving plasma cell leukemia or other blood cancers”
HENRY D. HERCE, MD
Dana-Farber Cancer Institute Boston, MA“Therapeutic reactivation of apoptosis in leukemia by targeting the control points of bax suppression.”
RUKHSANA ASLAM, MD
Feinstein Institute For Medical ResearchRole of the IL-17/TH17 in axis in generating a cytolytic immune response against chronic lymphocytic leukemia in B cells.
YILIANG WEI, PH.D.
Cold Spring Harbor Laboratories Cold Spring Harbor, NY“Probing leukemia vulnerabilities in vivo with domain-targeting CRISPR screening”
KEN MORITA, MD, PHD
Dana- Farber Cancer Institute, Boston, MA“Identification of Antileukemic Drugs Using
T-Cell Acute Lymphoblastic Leukemia Zebrafrish Models.”
FLORENCIA LETICIA PALACIOS, PHD
Feinstein Institute at Northwell Health Manhasset, NY“Characterization of the Biological Function
of Musashi2 RNA Binding Protein in Chronic Lymphocytic Leukemia”
FRIEDERIKE PASTORE, MD
Memorial Sloan Kettering Cancer Center New York, NY“Modeling Novel Translocations in Hematopoetic”
“Malignancies Using CIRPSR/Cas9.”
YUSUKE TARUMOTO, PHD
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY“Targeting Linked Dependency Between Kinase and Transcription Factor.”
PRABODHIKA MALLIKARATCHY, PHD
CUNY-Lehman College Bronx, NY“Design and Development of DNA Aptamer Based Immunotherapeutic”
In memory of Muriel Fusfeld
Grant made possible by Caryl Rubenfeld and The Muriel Fusfeld Foundation
KATRIEN VAN ROOSBROECK, PHD
University of Texas MD Anderson Cancer Center, Houston, TXAKIHIDE YOSHIMI, MD. PHD
Memorial Sloan Kettering Cancer Center New York, NYGrant is partially funded by Caryl Rubenfeld and The Muriel Fusfeld Foundation
FLORENCIA LETICIA PALACIOS. PHD
Feinstein Institute at Northwell Health Manhasset, NY“Characterization of the Biological Function of Musashi2 RNA Binding Protein in Chronic Lymphocytic Leukemia”
Grant made possible by Walter Kissinger
In memory of Ambassador Felix Schnyder
YUSUKE TARUMOTO, PHD
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY“Identification of Genetic Dependencies and Therapeutic Targets in AML”
Grant made possible by Walter Kissinger
In memory of Ambassador Felix Schnyder
YANA PIKMAN, MD
Dana-Farber Cancer Center, Boston, MAOLGA A. GURYANOVA, MD, PHD
Memorial Sloan Kettering Cancer Center, New York, NYPETER K. GREGERSON, MD & KIM STIMFENDORFER, PHD
North Shore-LIJ Feinstein Institute for Medical Research, Manhasset, NY“Small Molecules targeting PTPN22-Csk interaction to alter immune signaling thresholds.”
In memory of Muriel Fusfeld
Grant made possible by Caryl Rubenfeld and The Muriel Fusfeld Foundation
ANDREA NICOLA MAZZARELLO, PHD
North Shore-LIJ Feinstein Institute for Medical Research, Manhasset, NY“Immunoglobulin heavy chain isotype effects antibody reactivity and affinity and can lead to unabated B-cell stimulation in CLL”
Grant made possible by Walter Kissinger
In memory of Ambassador Felix Schnyder
YUSUKE TARUMOTO, PHD
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY“Identification of Genetic Dependencies and Therapeutic Targets in AML”
Grant made possible by Walter Kissinger
In memory of Ambassador Felix Schnyder
ANDREA NICOLA MAZZARELLO, PHD
North Shore-LIJ Feinstein Institute for Medical Research, Manhasset, NY“Immunoglobulin heavy chain isotype effects antibody reactivity and affinity and can lead to unabated B-cell stimulation in CLL”
Grant made possible by Walter Kissinger
In memory of Ambassador Felix Schnyder
JON A. OYER, PHD
Northwestern University“Consequences of the MMSET E1099K Mutation in Acute Lymphoblastic Leukemia (ALL)”
JOHN ANTO PULIKKAN, PHD
University of Massachusetts“Medical School Targeted Therapy for Core Binding Factor Leukemia”
JAE SEOK ROE, PHD
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY“Investigating p300-dependent Recruitment
Mechanism of Brd4″
Grant made possible by Walter Kissinger
In memory of Ambassador Felix Schnyder
GERARDO FERRER, PHD
The Feinstein Institute for Medical Research, North Shore-LIJ Health Systems, Manhasset, NY“An in vivo analysis of the cellular interaction governing the engraftment and growth of human chronic leukemia B Cells”
The grant was made possible by Walter Kissinger and The Ambassador Felix Schnyder Memorial Fund
In memory of Ambassador Felix Schynder
KOSHI AKAHANE, MD
Dana Farber Cancer Institute, Boston, MA“Significance of innate resistance to mitochondrial Apoptosis in high-risk T-ALL”
FAITH MERCAN, PHD
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY“Engineering Peptide-Based Brd4 Bromodomain”
“Inhibitors using Phage Display”
The grant was made possible by Walter Kissinger and The Ambassador Felix Schnyder Memorial Fund
In memory of Ambassador Felix Schnyder
KIM STIMPFENDORFER, PHD
The Feinstein Institute for Medical Research, North Shore-LIJ Health Systems, Manhasset, NY“Study of Characterization of proliferative and
Renewing cell populations in chronic CLL”
The grant was made possible by Caryl Rubenfeld of The Muriel Fusfeld Foundation
In memory of Muriel Fusfeld
SHINPEI KAWAOKA, PHD
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY“Targeting Bromodomain Proteins in Acute Lymphoblastic Leukemia”
Grant was made possible by Walter Kissinger and The Felix Schnyder Memorial Fund
In memory of Ambassador Felix Schnyder
RITA SIMONE, PHD
The Feinstein Institute for Medical Research North Shore, Manhasset, NY“A Novel Adoptive Transfer Model of Human Chronic Lymphocytic Leukemia Suggests a Key Role for T Lymphocytes in the Disease”
Grant was made possible by Walter Kissinger and The Ambassador Felix Schnyder Memorial Fund
In memory of Ambassador Felix Schnyder
ANDREW LANE, MD, PHD
Dana Farber Cancer Institute, Boston, MA“Defining Chromosome 21 Loci that Promote Lymphoid Leukemogenesis.”
In memory of Michael J. Lopez and Lauri Strauss
KIM STIMPFENDORFER, PHD
The Feinstein Institute for Medical Research North Shore, Manhasset, NY“B Lymphocyte Kinase (Blk): A Risk Gene for Autoimmunity and T-Cell Leukemia”
Grant was made possible by Caryl Rubenfeld and the Muriel Fusfeld Foundation
In memory of Muriel Fusfeld.
OMAR ABDEL-WAHAB, MD
Memorial Sloan Kettering Cancer Center, New York, NY“Role of ASXLI mutations in acute myelogenous leukemia”
This Grant was made possible by Mary Jo and John Boler
In memory of Richard J. Giffels, Helen DeGulis and Patricia Winkel
LYNE KHAIR, PHD
University of Massachusetts Medical School, Worcester, MA“Genome Wide DNA Breaks Induced by AID During B Cell Activation”
KIM STIMPFENDORFER, PHD
The Feinstein Institute for Medical Research North Shore – LIJ Health Systems, Manhasset, NY“B lymphocyte Kinase (Blk): a risk gene for autoimmunity and T cell leukemia”
This grant was made possible by Caryl P. Rubenfeld and The Muriel Fusfeld Foundation.
In memory of Muriel Fusfeld
RITA SIMONE, PHD
The Feinstein Institute for Medical Research North Shore – LIJ Health Systems, Manhasset, NY“A Novel Adoptive Transfer Model of Human Chronic Lymphocytic Leukemia”
“Suggests a Key Role for T Lymphocytes in the Disease”
This grant was made possible by Walter Kissinger and The Ambassador Felix Schnyder Memorial Fund
In Memory of Ambassador Felix Schnyder
EMMA VERNERSSON LINDAHL, PHD
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY“Investigating the Impact of TAp63 on Hematopoietic Malignancies Utilizing
a Novel TAp63-Deficient Mouse Model.”
DAVIDE BAGNARA, PHD
The Feinstein Institute for Medical Research, North Shore-LIJ Health Systems, Manhasset, NY“Development of an Adoptive Transfer Model of Human Chronic Lymphocytic Leukemia”
This Grant was made possible by Walter Kissinger and The Ambassador Felix Schnyder Memorial Fund
In Memory of Ambassador Felix Schnyder
YUCHEN CHIEN, PHD
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY“Critical Contribution of NF-kB to Chemoresistance of Myc and Bc12 Driven Lymphoma in Mice”
This Grant was made possible by Walter Kissinger and The Ambassador Felix Schnyder Memorial Fund
In Memory of Ambassador Felix Schnyder
PATRICIA ERNST, PHD
Dartmouth Medical School, Hanover, NH“Genetic and Biochemical Approaches to Targeting Mixed Lineage Leukemia”
MONICA L. GUZMAN, PHD
Joan & Sanford I. Weill Medical College of Cornell University, New York, NY“Targeting of Human Acute Myelogenous Leukemia Stem Cells”
RAJESH R. SINGH, PHD
University of Texas MD Anderson Cancer Center, Houston, Texas“Targeting Sonic Hedgehog Signaling to Overcome Chemoresistance in Diffuse Large B-Cell Lymphoma”
EMILY S. TONOREZOS, MD, MPH
Sloan Kettering Institute for Cancer Research, New York, NY“Diet and Insulin in Survivors of Childhood Leukemia”
This Grant was made possible
by MaryJo and John Boler
In Memory of Helen DeGulis, Richard J. Giffels, Donald George Uhlir, and Patricia Winkel.
IKBEL ACHOUR, PHD
University of Illinois at Chicago, Springfield, ILMechanisms of Chromosomal Translocation
In B Lymphocytes
This Grant was made possible
by Mary Jo and John Boler
In Memory of Richard J. Giffels
SHIH-SHIH CHEN, PHD
Feinstein Institute for Medical Research, North Shore-LIJ Health Systems, Manhasset, NYRole of B-cell Antigen Receptor Engagement in Chronic Lymphocytic Leukemia: Survival and Expansion Versus Anergy and Death
This Grant was made possible by Walter Kissinger and The Ambassador Felix Schnyder Memorial Fund
In Memory of Ambassador Felix Schnyder
YA-HUEI KUO, PHD
Beckman Research Institute of City of Hope, Duarte, CAAnalysis and Targeting of Leukemia Stem Cells in Inv(16)-Associated Acute Myeloid Leukemia
This grant was made possible by Mary Jo and John Boler In Memory of Helen DeGulis
CORNELIOUS MIETHING, MD
Cold Spring Harbor Laboratory, Cold Spring Harbor, NYStudy on the Role of PTEN in Tumorigenesis and Development of Chemoresistance in a MiR30-Based Transgene Murine Model of Conditional PEN Inactivation.
This Grant was made possible by Walter Kissinger and The Ambassador Felix Schnyder Memorial Fund
In Memory of Ambasador Felix Schnyder
RUSHDIA YUSUF, MD, MPH
Massachusetts General Hospital, Boston, MassThe Role of UDP-Glucose in Protection of A Hematopoietic Stem Cells from Chemotherapy
This Grant was made possible by MaryJo and John Boler
In Memory of Patricia WInkel
CAMILE P. SEMIGHINI, PHD
Cold Spring Harbor Laboratory, Cold Spring Harbor, NYUse of reversible RNA interference in transgenic mice to study the importance of RB and ATM in tumor
development, maintenance and response to therapy.
Ambassador Felix Schnyder Memorial Grant
In Memory of Ambassador Felix Schnyder
CARLO CALISSANO, MD
The Feinstein Institute for Medical Research, North Shore – LIJ Health Systems, Manhasset, NYIdentification and characterization of chronic lymphocytic leukemia B cells and their normal B.
lymphocyte counterpart
Ambassador Felix Schnyder Memorial Grant
In Memory of Ambassador Felix Schnyder
JAMES L. LABELLE, M.D., PHD
Dana-Farber Cancer Institute, Boston, MATitle Dismantling the Apoptotic Blockade of Refractory Leukemia by Pharmacologic Replacement of the Tumor Suppressor BIM
This Grant Made Possible by Muriel Fusfeld Foundation
FILIZ SEN, MD
New York University School of Medicine, New York, NYTitle FBN7 Mutations in T Cell ALL
This Grant made possible by Mary Jo and John Boler
In Memory of Helen DeGulis
ANGELA STODDART, PHD
The University of Chicago, Chicago, ILDetermining the Transforming Mechanism of the CLAM-AF10 fusion Protein: Does Defective Endocytosis Synergize with Transcriptional Deregulation?
This Grant Made Possible by Mary Jo and John Boler
In Memory of Richard J. Giffels
LILI WANG, MD
University of Illinois at Chicago, Chicago, ILTitle Mechanisms of Chromosomal
Translocation in B Lymphocytes
This Grant made possible by Mary Jo and John Boler
In Memory of Patricia Winkel
ELEANA LEVANTINI, PHD
Beth Israel Deaconess Medical Center, Boston, MassDevelopment of transgenic models to mimic human leukemias: the BVR/ABL case
Ford Motor Company Fund and The Johnny Mercer Foundation for their assistance in making this grant possible.
JAN ANDREAS BURGER, MD
M.D. Anderson Cancer Center, Houston, TXPhosphoinositide 3-Kinases in Chemokine
Receptor Signaling in Chronic Lymphocytic Leukemia
Made Possible by Mary Jo and John Boler
In Memory of Helen DeGulis
JAVIER PINILLA-IBARZ, MD, PHD
H. Lee Moffitt Cancer Center, Tampa, FLCorrelative Immunological Studies of a Pilot Trial With a WTl Analog Peptide Vaccine in
Patients With Myeloid Malignancies
Made Possible by Mary Jo and John Boler
In Memory of Richard J. Giffels
MONICA BUZZAI, PHD
Northwestern University Feinberg School of Medicine, Chicago, ILCell Survival and Proliferation Pathways Mediated by JAK2 Mutations in Myeloproliferative Disorders (MPD) and Leukemia Made
Possible by Mary Jo and John Boler
In Memory of Patricia Winkel
B. BELINDA DING, PHD
Albert Einstein College of Medicine, Bronx, NYMechanism of STAT3 Activation in Diffuse
Large B-cell Lymphoma
Made Possible by Ford Motor Company and
The Johnny Mercer Foundation
In Memory of Johnny Mercer
RAMIRO GARZON, MD
The Ohio State University, Columbus, OHRole of MicroRNA in the Pathogenesis of Acute
Myeloid Leukemia
Made Possible by the Friends of José Carreras
International Leukemia Foundation
ROSA CATERA, PHD
The Feinstein Institute for Medical Research, North Shore – LIJ Health System, Manhasset, NYBacterial Components as Epitopes for B-CLL
Antibodies
Made Possible by the Ambassador Felix
Schnyder Memorial Fund
In Memory of Ambassador Felix Schnyder
TIMOTHY S. PARDEE, MD, PHD
Cold Spring Harbor Laboratory, Cold Spring Harbor, NYCorrelative Immunological Studies of a Pilot Trial With a WTl Analog Peptide Vaccine in
In Vitro Array Based Screening for Genes Involved in Chemoresistance and
Sensitivity in Acute Myelogenous Leukemia
Made Possible by the Ambassador Felix Schnyder Memorial Fund
In Memory of Ambassador Felix Schnyder
DONG HONG CAI, MD, PHD
John Hopkins University, Baltimore, MDInteraction Between C/EBPa and AP-1 in
Myeloid Leukemogenesis
Grant made possible by Mary Jo and John Boler
In memory of Patricia Winkel
SCOTT CAMERON, MD, PHD
U T Southwestern Medical Center, Dallas, TXMechanism of Programmed Cell Death in
MI1- positive Leukemia
Grant made possible by Mary Jo and John Boler
In Memory of Helen DeGulis
NOBUHARU FUJII, MD, PHD
Fred Hutchinson Cancer Research Center, Seattle,WATranscription Factors in Hematopoietic Stem Cells As Targets For Leukemia Immunotherapy
Grant Made Possible by Mary Jo and John Boler
In Memory of Richard J. Giffels
ANN JAKUBOWSKI, MD, PHD
Memorial Sloan Kettering Cancer Center, New York, NYClinical and Laboratory Studies of Keratinocyte
Growth Factor to Facilitate Immune
Reconstitution in Patients Undergoing an Allergenic Stem Cell Transplant Grant made possible by Alvin Marks In Memory of Elaine Marks
HANNO HOCK, MD, PHD
Massachusetts General Hospital, Boston, MARe-creation of Leukemogenic TEL-AML1
Fusion in Embryonic Hematopoiesis
Grant made possible by The Muriel Fusfeld Foundation
In Memory of Muriel Fusfeld
H. DANIEL LACORAZZA, PHD, PI
Baylor College of Medicine, Dallas, TXRegulation of ELF-4 Gene Expression in Leukemic Cells
Grant made possible by Ford Motor Company and by the Johnny Mercer Foundation
In Memory of Johnny Merce
BRIAN MCCARTHY, PHD
North Shore / Long Island Jewish Health System Manhasset, NYAnalysis of Patient Parameters Related to the
B-Cell Receptors to Chronic Lymphocytic
Leukemias
Grant made possible by The Ambassador Felix Schnyder Fund
In Memory of Ambassador Felix Schnyder
JOHANNES ZUBER, MD
Cold Spring Harbor Labaoratory, Cold Spring Harbor,NYIn-Vivo Analysis of Key Genes and Mechanisms
of Resistance in the Therapy of Active Myeloid
Leukemia
Grant made possible by The Ambassador Felix
Schnyder Fund
In Memory of Ambassador Felix Schnyder
DEEPA TRIVEDI, MD
Memorial Sloan Kettering Cancer Center,NYGeneration of Cytomegalovirus (CMV) Specific
T- Lymphocytes using Protein Spanning Pools of Pentadecapeptides for Adoptive Immuno Therapy
Grant made possible by Mary Jo and John Boler
In Memory of Patricia Winkel
FARSHID DAYYANI, MD
Massachusetts General Hospital, Boston, MAThe Role of Groucho Family Co-Repressors
TLE1 and TLE4 in Hematopoiesis and Leukemogenesis
Grant made possible by Mary Jo and John Boler
In Memory of Helen DeGulis
MANABU SHIMOYAMA, MD, PHD
Mount Sinai School of Medicine, NY, NYThe Importance of the SET Domain and Histone
Methylation in Leukemia and Other Hematological
Malignancies
Grant made possible by Mary Jo and John Boler
In Memory of Donald George Uhlir, DVM
FLORENCE BERNARDIN FRIED, PHD
Johns Hopkins Hospital, Baltimore, MDRegulation of Proliferation by the AML 1
Leukemia Oncoprotein
Grant made possible by Ford Motor Company
DANIEL DITZEL SANTOS, MD
Dana Farber Cancer Center, Boston, MATargeting Mast Cells and Mast Cell Interactions in the Treatment of Waldenstrom’s Macroglobulinemia
Grant made possible by The Muriel Fusfeld
Foundation In Memory of Muriel Fusfeld
CLAUDIA S. HUETTNER, PHD
Blood Center Institute of Blood Center of Wisconsin Milwaukee, WIRole of Bcl-x Leukemogenesis by BCR/ABL
Grant made possible by The Johnny Mercer
Foundation In Memory of Johnny Mercer
MANABU SHIMOYAMA, MD, PHD
Mount Sinai School of Medicine, NY, NYThe Importance of the SET Domain and Histone
Methylation in Leukemia and Other Hematological
Malignancies
Grant made possible by Mary Jo and John Boler
In Memory of Donald George Uhlir, DVM
DANIEL DITZEL SANTOS, MD
Dana Farber Cancer Center, Boston, MATargeting Mast Cells and Mast Cell Interactions in the Treatment of Waldenstrom’s Macroglobulinemia
Grant made possible by The Muriel Fusfeld
Foundation In Memory of Muriel Fusfeld